Ishikita T, Ishiguro A, Fujisawa K, Tsukimoto I, Shimbo T
Department of Pediatrics, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Japan.
Am J Hematol. 1999 Sep;62(1):52-5. doi: 10.1002/(sici)1096-8652(199909)62:1<52::aid-ajh9>3.0.co;2-e.
Carbamazepine (CBZ), a widely used anticonvulsant, occasionally causes serious hematologic disorders. A 12-year-old boy was admitted because of a diffuse petechial rash and profound thrombocytopenia (10 x 10(9) platelets/l), after having been treated for epilepsy with CBZ for 12 days. Seven days following withdrawal of CBZ and initiation of prednisolone therapy, the platelet count recovered. In a subsequent challenge test with CBZ, platelet counts again decreased, and the levels of platelet-associated IgG and serum interleukin-6 increased. No antibodies against platelet glycoprotein IIb/IIIa or Ib were detected in plasma. We believe that this is the first reported occasion when CBZ-induced thrombocytopenia has been defined by a rechallenge test.
卡马西平（CBZ）是一种广泛使用的抗惊厥药，偶尔会引起严重的血液系统疾病。一名12岁男孩因弥漫性瘀点皮疹和严重血小板减少（血小板计数为10×10⁹/L）入院，此前他已用CBZ治疗癫痫12天。停用CBZ并开始泼尼松龙治疗7天后，血小板计数恢复。在随后的CBZ激发试验中，血小板计数再次下降，血小板相关IgG和血清白细胞介素-6水平升高。血浆中未检测到抗血小板糖蛋白IIb/IIIa或Ib的抗体。我们认为，这是首次通过激发试验确定CBZ诱导的血小板减少症的报道。
